| |
ASM/ICAAC: Tenofovir Alafenamide Has Wide Efficacious Range for Treatment of HIV-1 Infection: Pharmacokinetic-Pharmacodynamic Relationship From a Phase 3 Study
|
| |
| |
Reported by Jules Levin
ASM/ICAAC 2016 June 16-20 Boston, MA
ASM/ICAAC 2016 Joseph M. Custodio, Lillian S. Ting, Julia Z. Zack, Sophia R. Majeed, Mingjin Yan, Lijie Zhong, Martin S. Rhee
Gilead Sciences, Inc., Foster City, CA
*Study drugs taken without regard to food; †FTC/TAF dose: 200/10 mg with boosted protease inhibitors (PIs) and 200/25 mg with unboosted 3rd agents; ‡FTC/TAF 200/10 mg: ATV+RTV (n=53), DRV+RTV (n=84), LPV/r (n=18); FTC/TAF 200/25 mg: DTG (n=26), NVP (n=74), RAL (n=66), EFV (n=8), RPV (n=3), MVC (n=1); §FTC/TDF 200/300 mg: ATV+RTV (n=50), DRV+RTV (n=82), LPV/r (n=18); FTC/TAF 200/25 mg: DTG (n=23), NVP (n=66), RAL (n=73), EFV (n=6), RPV (n=6), MVC (n=6). BL, baseline; eGFR, estimated glomerular filtration rate.
|
|
| |
| |
|
|
|
